Stem cells cannot cure herpes today. There is no FDA-approved stem cell therapy, vaccine, or any other treatment that eliminates herpes simplex virus (HSV-1 or HSV-2) from the body. However, stem cells play an increasingly important role in herpes research, both as laboratory tools and as potential delivery vehicles for future therapies. The most promising advances in this space actually involve gene editing rather than stem cells alone.
Why Herpes Is So Hard to Cure
The core challenge with herpes is latency. After the initial infection, the virus retreats into nerve clusters called ganglia and essentially goes dormant. Current antiviral medications like valacyclovir only work against the virus while it’s actively replicating. They can reduce outbreaks and lower the risk of transmission, but they cannot touch the virus while it’s hiding in nerve tissue. As the NIH’s 2023-2028 strategic plan for herpes research states plainly: there is currently no cure, and individuals remain infected for life.
This is the fundamental obstacle for any potential therapy, stem cell-based or otherwise. A true cure would need to either reach the virus inside those nerve cells and destroy it, or permanently arm the immune system to suppress it without ongoing medication. Neither goal has been achieved yet.
How Stem Cells Fit Into Herpes Research
Stem cells are involved in herpes science in several ways, though none of them amount to a cure at this stage.
The most practical use right now is in the lab. Researchers use stem cells to grow organoids, which are tiny three-dimensional clusters of cells that mimic real organs. These allow scientists to study how HSV infects different cell types and how the immune system responds. Neurons grown from induced pluripotent stem cells have been used to model HSV-1 infection, though reliably recreating the latency and reactivation cycle in these lab-grown human cells has proven difficult.
A second area involves mesenchymal stem cells (MSCs), a type of stem cell found in bone marrow, fat tissue, and other sources. MSCs have natural immune-modulating properties. When researchers infected fat-derived MSCs with different strains of HSV-1 and HSV-2, the cells showed significant changes in 16 different immune signaling molecules involved in inflammation and tissue repair. The infected cells activated pathways tied to antiviral defense, including interferon signaling and viral pattern recognition. This research helps scientists understand how the immune system interacts with herpes at a cellular level, but it hasn’t translated into a treatment.
MSCs have also been tested as delivery vehicles for other viruses in cancer research. They can successfully carry engineered viruses to target cells. This concept of using stem cells as a “Trojan horse” to deliver therapeutic payloads is being explored across medicine, but it hasn’t been applied to herpes treatment in any clinical trial.
Gene Editing Shows More Promise Than Stem Cells Alone
The most exciting progress toward a herpes cure doesn’t come from stem cells directly. It comes from gene-editing technology. Researchers at Fred Hutch Cancer Center reported in 2024 that an experimental gene-editing therapy eliminated 90% of HSV-1 after oral infection in mice and 97% after genital infection. This approach uses molecular scissors to cut the viral DNA hiding inside nerve cells, essentially destroying the latent virus at its source.
This is a fundamentally different strategy from stem cell therapy. Rather than modulating the immune system or delivering drugs, gene editing targets the viral genetic material itself. The NIH considers a “functional cure,” meaning sustained suppression of viral shedding without ongoing treatment, to be an achievable near-term goal even if complete eradication of every viral particle remains difficult. Gene editing is currently the most advanced approach toward that goal.
Bone Marrow Transplants Don’t Eliminate Herpes
Some people wonder whether hematopoietic stem cell transplants (bone marrow transplants) could reset the immune system and clear herpes. The evidence says no. Research on bone marrow transplant recipients found that patients frequently experienced herpes recurrences after transplant, and in some cases the recurrences were more severe than before. Patients whose immune systems mounted a strong response after their first post-transplant outbreak had fewer subsequent recurrences (13 out of 28 versus 18 out of 19 in those with weaker responses), but the virus was not eliminated.
This makes sense biologically. A bone marrow transplant replaces the blood-forming system, but it doesn’t reach the nerve ganglia where herpes hides. The virus remains in its latent reservoir regardless of what happens to the immune system.
Safety Concerns With Stem Cell Treatments
If you’ve seen clinics advertising stem cell treatments for herpes, there are real reasons for caution. Unregulated stem cell therapies carry documented risks, and some are particularly relevant for people with viral infections.
Mesenchymal stem cells from donors can harbor viral DNA themselves. Testing of MSCs from healthy donors has found genetic material from several viruses, including members of the herpesvirus family. Additionally, viral contamination can occur during cell processing and culture in the lab. Established medical protocols now require PCR testing for herpesviruses before any MSC transplantation.
MSCs are also known to suppress immune responses. While this property is useful for treating autoimmune conditions, it’s a potential liability in someone with a chronic viral infection. Suppressing the immune system could theoretically allow herpes to reactivate more frequently or severely. Systemic MSC administration has been linked to increased risk of serious infections, including pneumonia-related deaths in some transplant settings.
Where Things Stand
The honest picture is that stem cells are a research tool for herpes, not a treatment. They help scientists understand the virus better, model infection in the lab, and potentially serve as delivery mechanisms for future therapies. But no stem cell therapy has entered clinical trials for herpes, and no evidence suggests that stem cells alone can reach or eliminate the virus hiding in nerve tissue.
The NIH’s strategic plan for 2023-2028 focuses on developing vaccines, improving understanding of latency, and pursuing functional cures. Gene-editing approaches are further along than any stem cell-based strategy. Multiple vaccine candidates are also in development, with early-phase clinical trials underway to test safety and immune response. For now, antiviral medications remain the only proven way to manage herpes, reducing outbreak frequency and transmission risk but not eliminating the virus.